Navigating 2026 ISO 10993-1 Updates: A Strategic Guide for MedTech

Navigating Anticipated 2026 ISO 10993-1 Updates: A Strategic Guide for Medical Device Manufacturers --- With significant updates to the foundational biocompatibility standard, ISO 10993-1, anticipated around 2026, medical device manufacturers face a critical need to evolve their approach to biological safety evaluation. The expected changes continue the shift away from a simple checklist of in vivo tests and toward a more rigorous, risk-based framework centered on comprehensive material and chemical characterization. This evolution requires a proactive, strategic adjustment to how biological risk is assessed for both new and existing devices. Successfully navigating this landscape means moving beyond a "wait and see" approach. Manufacturers can take concrete steps now to align their processes with these emerging expectations. This involves reinforcing the Biological Evaluation Plan (BEP) as a central strategic document, deepening the understanding of manufacturing processes and material supply chains, and systematically re-evaluating legacy devices. For devices with novel materials or complex biological interactions, early engagement with regulatory bodies like the FDA through its Q-Submission program becomes an essential de-risking tool. ## Key Points * **Risk-Based Framework is Paramount:** The updates are expected to further solidify a holistic, risk-based methodology. The goal is not just to complete tests, but to thoroughly understand and mitigate biological risks based on scientific rationale, with a strong emphasis on reducing and replacing animal testing where justified. * **Chemical Characterization as the Foundation:** A comprehensive understanding of device materials and potential leachables is no longer optional; it is the cornerstone of a modern biological evaluation. Regulators expect robust analytical chemistry data to inform a toxicological risk assessment. * **The BEP is a Living Strategic Document:** The Biological Evaluation Plan (BEP) must be a comprehensive, scientifically sound document that justifies the entire evaluation strategy. It should detail the device, its materials, manufacturing processes, intended use, and the rationale for the specific testing (or lack thereof) being conducted. * **Proactive Gap Analysis is Essential:** Manufacturers cannot assume that historical biocompatibility data for existing devices will remain sufficient. A formal gap analysis is needed to assess legacy data against the new standard's expectations, particularly regarding chemical characterization and toxicological risk. * **Supplier and Process Controls are Critical:** A robust biocompatibility profile requires deep knowledge and control over the entire supply chain and manufacturing process. Undocumented changes in raw material suppliers or processing aids can invalidate previous testing and introduce significant regulatory risk. * **Early Regulatory Engagement De-Risks Strategy:** For devices with novel materials, complex designs, or when proposing to omit standard tests, the FDA's Q-Submission program provides an invaluable mechanism for gaining feedback and alignment on a biocompatibility strategy before significant resources are invested. ## The Evolving Philosophy of Biocompatibility: From Testing to Total Risk Assessment The guiding principle behind the evolution of ISO 10993-1 is the move from a prescriptive, test-focused approach to a holistic risk management process. Historically, biocompatibility was often treated as a checklist of endpoints to be satisfied through a predefined battery of tests. The modern approach, embraced by global regulators including the FDA, views biological safety as an integral part of the overall risk management process governed by ISO 14971. This philosophy is built on a deeper scientific understanding of material-tissue interactions. Instead of simply observing the outcome of an animal test, the focus is now on proactively identifying and assessing the potential hazards—primarily the chemical constituents that can be released from a device during use. This aligns with the "3Rs" principle (Replacement, Reduction, and Refinement of animal testing), encouraging manufacturers to use analytical chemistry and in vitro models to answer safety questions whenever possible. ## Structuring a Future-Ready Biological Evaluation Plan (BEP) The BEP is the most critical document in a biological evaluation. It is not merely a summary of test results but the comprehensive roadmap and scientific justification for the entire biocompatibility strategy. A robust BEP should be structured as a living document and contain the following key elements: 1. **Comprehensive Device Description:** This goes beyond basic dimensions. It must include a complete list of all patient-contacting materials, including colorants, adhesives, and processing aids, with specific material standards (e.g., ASTM, ISO) cited. 2. **Detailed Intended Use:** Clearly define the nature of body contact (e.g., surface, implant), the duration of contact (limited, prolonged, permanent), and the intended patient population. 3. **Thorough Material and Chemical Characterization Plan:** Detail the plan for identifying and quantifying the device's chemical constituents. For complex devices, this often involves extensive extractables and leachables (E&L) studies. 4. **Manufacturing Process Assessment:** Document every step of the manufacturing process that could impact biocompatibility. This includes molding, machining, cleaning, sterilization (and any residues), packaging, and assembly. Identify any potential contaminants or process residuals. 5. **Identification of Biological Endpoints:** Systematically identify all relevant biological endpoints from ISO 10993-1, Table A.1, based on the device's category of contact. 6. **Information Gathering and Literature Review:** Systematically search for and evaluate existing data on the device materials, including clinical history, supplier data, and published literature. 7. **Risk Assessment and Testing Justification:** This is the core of the BEP. For each identified biological endpoint, conduct a risk assessment. Based on the material characterization and existing data, provide a clear, scientific rationale for the proposed evaluation strategy. This includes justifying why certain biological tests are necessary or, more importantly, *why they are not necessary* and can be addressed by a toxicological risk assessment of the chemical characterization data. 8. **Conclusion on Biological Safety:** The BEP should conclude with a summary statement on the overall biological safety of the medical device, supported by the evidence and analysis presented. ## A Framework for Legacy Device Gap Analysis For devices already on the market, manufacturers must conduct a formal gap analysis to ensure their existing documentation meets the heightened expectations. Assuming prior clearance or approval is sufficient is a significant compliance risk. A structured gap analysis framework includes the following steps: 1. **Inventory and Review:** Compile the complete design and manufacturing history for the device, including the original biocompatibility test reports and any documented changes to materials, suppliers, or processes since the initial testing. 2. **Map Existing Data to Current Requirements:** Create a matrix comparing the historical test data against all relevant endpoints from the current version of ISO 10993-1. Pay close attention to whether the original testing was supported by robust chemical characterization. 3. **Assess Manufacturing and Supplier Changes:** This is a critical and often overlooked step. Has a raw material supplier been changed? Is a new mold release agent being used? Any such change, even if deemed minor at the time, can impact the device's biocompatibility profile and may necessitate a new risk assessment. 4. **Conduct a Toxicological Risk Assessment (TRA):** If sufficient chemical data exists (or can be generated), a qualified toxicologist can assess the potential health risks of identified compounds. A TRA can often be used to justify that residual risks are acceptable without further animal testing. 5. **Identify and Address Gaps:** If the analysis reveals gaps—such as missing chemical information, unaddressed endpoints, or unevaluated manufacturing changes—develop a remediation plan. This plan might involve new chemical characterization studies, targeted in vitro tests, or a documented risk assessment to justify the absence of further testing. ## Scenarios: Applying the Strategy ### Scenario 1: Long-Term Implantable Sensor with a Novel Polymer Coating A manufacturer is developing a new glucose sensor intended for permanent implantation, featuring a novel polymer coating designed to improve biocompatibility and reduce fouling. * **What Regulators Will Scrutinize:** The novelty of the material and its degradation profile over the device's lifetime will be the primary focus. Regulators will expect an exhaustive understanding of what could leach from this coating into the body over many years. * **Critical Data to Provide:** A simple battery of standard biocompatibility tests will be insufficient. The strategy must be anchored in an aggressive chemical characterization program, including accelerated degradation studies and exhaustive extraction studies to identify all potential leachables. This data must feed into a comprehensive toxicological risk assessment for every identified compound. The justification for the Analytical Evaluation Threshold (AET) will be heavily scrutinized. Depending on the risks identified, long-term implantation studies may still be required. ### Scenario 2: Single-Use Catheter (Transient Contact) with a New Colorant Supplier A company manufactures a Class II catheter and is forced to change the supplier for the blue colorant used in the polymer hub due to supply chain issues. The new colorant has the same chemical name but is from a different source. * **What Regulators Will Scrutinize:** The assumption that the new colorant is "equivalent" without data. Regulators will want to see a documented risk assessment demonstrating that the change does not introduce new biological risks from impurities or different manufacturing residuals from the new supplier. * **Critical Data to Provide:** The manufacturer should first obtain detailed chemical information from the new supplier. A comparative chemical characterization (e.g., using techniques like GC/MS or LC/MS) on extracts from both the old and new materials would be a robust approach. This data, combined with a toxicological risk assessment, could be used to justify that the change is low-risk and that a full suite of biological testing is not necessary, potentially limiting the need to only repeat sensitive in vitro tests like cytotoxicity. The entire analysis must be documented in an updated BEP. ## Strategic Considerations and the Role of Q-Submission For complex biocompatibility questions, early and transparent communication with regulators is the most effective de-risking strategy. The FDA's Q-Submission program is a formal mechanism for sponsors to request feedback on their regulatory strategies, including biocompatibility test plans, before submitting a marketing application. A Q-Submission is particularly valuable in the following situations: * **Use of Novel Materials:** When a device incorporates materials with no history of use in medical devices. * **Justifying Omission of Tests:** When a sponsor plans to use chemical characterization and toxicological risk assessment to justify waiving one or more standard biological tests recommended by the standard. * **Complex Devices:** For devices with intricate designs, multiple material components, or challenging patient contact profiles where standard test methods may not be appropriate. * **Post-Gap Analysis Confirmation:** After conducting a gap analysis for a legacy device, a sponsor may use a Q-Submission to seek FDA's agreement with their conclusion that the existing data and risk assessment are sufficient to address all relevant endpoints. ## Key FDA References When developing a biocompatibility strategy for the US market, sponsors should rely on the latest official documents. While standards evolve, key foundational references include: * FDA's Guidance on the Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process." * FDA's Q-Submission Program guidance. * General regulations for premarket submissions, such as those found under 21 CFR Part 807, Subpart E for Premarket Notification (510(k)). Sponsors should always consult the FDA website for the most current versions of these and other relevant guidance documents. ## Finding and Comparing Biocompatibility Testing Services Providers Choosing the right partner for biocompatibility evaluation is as critical as the strategy itself. A qualified provider is more than just a testing laboratory; they are a strategic partner who can help navigate complex requirements. When evaluating providers, look for: * **Accreditation and Expertise:** The laboratory should be ISO 17025 accredited. Crucially, they should have demonstrated experience with your specific device type and materials. * **Integrated Services:** A provider that offers in-house expertise across analytical chemistry (E&L), toxicology, and traditional biological testing can provide a more seamless and integrated evaluation, preventing communication gaps between different specialists. * **Strategic Input:** The best partners will not just run tests. They will review your BEP, challenge your assumptions, and help you build a scientifically sound justification for your strategy. Ask if they have staff toxicologists and regulatory experts who can contribute to the overall plan. * **Regulatory Familiarity:** The provider should have extensive experience with submissions to your target regulatory bodies (e.g., FDA, EU Notified Bodies) and understand their current expectations. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. --- This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*